#	Pagina
attuale pagina	/open-h2020/projects/222859/index.html

Opendata, web and dolomites

MS4Drug SIGNED

An Innovative Mass Spectrometry-Based Workflow for Drug Discovery

Total Cost €

EC-Contrib. €

Partnership

Views

MS4Drug project word cloud

Explore the words cloud of the MS4Drug project. It provides you a very rough idea of what is the project "MS4Drug" about.

ms resolved treatment proteins exchange spectrometry drug cell coiled arterial effect isolated drugs coil molecular conformational biochemical protein mapped anti hdx patients linking reagent company preclinical rho pharmaceutical integrate conjunction candidates environment survival pah perspectives cellular pharmacological life containing biology vitro insights opens xlms time kinase hydrogen inhibitors interactions routine rate mass outcome herein companies conformations pulmonary tested italy pipeline chiesi lining gain interaction biotechnological elucidate hypertension discovery threatening rock structural complements validation trials underlying signaling interactome deuterium pharma decipher systematic mechanisms cross unmatched pharmaceuticals modulating first develops 60

Project "MS4Drug" data sheet

The following table provides information about the project.

Coordinator	CHIESI FARMACEUTICI SPA Organization address address: Via Palermo 26/a city: Parma postcode: 43122 website: www.chiesigroup.com contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.
Coordinator Country	Italy [IT]
Total cost	171˙473 €
EC max contribution	171˙473 € (100%)
Programme	1. H2020-EU.1.3.2. (Nurturing excellence by means of cross-border and cross-sector mobility)
Code Call	H2020-MSCA-IF-2018
Funding Scheme	MSCA-IF-EF-SE
Starting year	2019
Duration (year-month-day)	from 2019-07-01 to 2021-06-30

Partnership

Take a look of project's partnership.

#	participants	country	role	EC contrib. [€]
1	CHIESI FARMACEUTICI SPA CHIESI FARMACEUTICI SPA Organization address address: Via Palermo 26/a city: Parma postcode: 43122 website: www.chiesigroup.com contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	IT (Parma)	coordinator	171˙473.00

Map

Project objective

Pulmonary Arterial Hypertension (PAH) is a life-threatening condition; even if treated, patients only have a 5-year survival rate of less than 60%. For the treatment of PAH, Chiesi Pharmaceuticals develops Rho-associated, coiled-coil-containing protein kinase (ROCK) inhibitors. The aim of this project is to elucidate conformational changes in ROCK in vitro as well as in the cellular environment that are induced by anti-PAH drug candidates, which are currently being tested in preclinical trials at Chiesi Pharmaceuticals. The ROCK interactome will be mapped to gain detailed insights into the molecular mechanisms underlying the signaling pathways of ROCK. We will decipher the effect of anti-PAH drug candidates on the ROCK interactome and elucidate drug-induced conformational changes in ROCK. Identifying novel pharmacological targets modulating specific ROCK/protein interactions will eventually lead to novel drugs for an improved treatment of PAH. This project will integrate, for the first time, in cell cross-lining mass spectrometry (XLMS), in conjunction with hydrogen/deuterium exchange mass spectrometry (HDX-MS), in the drug discovery pipeline of a pharma company. It will be the first application of the XLMS approach in the field of structural biology in Italy. The conformations and interactions of ROCK, derived by in cell XLMS, will allow a systematic validation of in vitro biochemical studies. This project aims to advance the in cell XLMS approach into a routine method for drug discovery on the system-wide level that complements HDX-MS studies using isolated proteins. Novel cross-linking reagent will be developed to bring the XLMS approach to a new level of time-resolved protein interaction studies. As such, the integrated approach described herein opens unmatched and novel perspectives for biotechnological and pharmaceutical companies. The outcome of this project is expected to have a large impact on structural biology and drug discovery in general.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "MS4DRUG" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "MS4DRUG" are provided by the European Opendata Portal: CORDIS opendata.